Vertex Pharma (VRTX) November 11 weekly option implied volatility into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Vertex (VRTX) PT Raised to $451 at RBC Capital
November 5, 2024 7:00 AM ESTRBC Capital analyst Brian Abrahams raised the price target on Vertex (NASDAQ: VRTX) to $451.00 (from $437.00) while maintaining a Sector Perform rating.
The analyst comments "CF beat and raise shows the continued health of the company's core franchise and is likely to perpetuate... More
